We are live on ! Find out more
CPRX

Catalyst Pharmaceutical
CPRX

Delisted

CPRX was delisted on the 14th of July, 2026.

Back to rankings

131 hedge funds and large institutions have $254M invested in Catalyst Pharmaceutical in 2020 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 44 increasing their positions, 49 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

243% more call options, than puts

Call options by funds: $819K | Put options by funds: $239K

11% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 19

8% more capital invested

Capital invested by funds: $236M → $254M (+$18.3M)

2.78% more ownership

Funds ownership: 60.98% → 63.76% (+2.8%)

1% more funds holding

Funds holding: 130 → 131 (+1)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

10% less repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 49

Holders
131
Holders Change
+1
Holders Change %
+0.77%
% of All Funds
2.89%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
21
Increased
44
Reduced
49
Closed
19
Calls
$819K
Puts
$239K
Net Calls
+$580K
Net Calls Change
+$850K

Top Buyers

Rank Fund Capital Flow
1
MP
Mangrove Partners
Connecticut
+$11.5M
2
PVI
Pura Vida Investments
New York
+$5.94M
3
OM
Opaleye Management
Massachusetts
+$4.31M
4
Schroder Investment Management Group
Schroder Investment Management Group
United Kingdom
+$4M
5
Millennium Management
Millennium Management
New York
+$3.29M

Top Sellers

Rank Fund Capital Flow
1
N
Nuveen
North Carolina
-$7.18M
2
Squarepoint
Squarepoint
New York
-$3.11M
3
Prudential Financial
Prudential Financial
New Jersey
-$3.04M
4
Two Sigma Investments
Two Sigma Investments
New York
-$2.87M
5
Arrowstreet Capital
Arrowstreet Capital
Massachusetts
-$2.74M
Name Holding Trade Value Shares
Change 		Change in
Stake
GCM
26
Gables Capital Management
Florida
$1.98M -$20.5K -5,000 -1%
Deutsche Bank
27
Deutsche Bank
Germany
$1.88M -$9.32K -2,272 -0.5%
JGC
28
J. Goldman & Co
New York
$1.75M +$1.87M +454,773 New
QI
29
QS Investors
New York
$1.73M – – –
Two Sigma Advisers
30
Two Sigma Advisers
New York
$1.7M -$65.3K -15,900 -3%
Bank of New York Mellon
31
Bank of New York Mellon
New York
$1.65M -$21.9K -5,324 -1%
N
32
Nuveen
North Carolina
$1.54M -$7.18M -1,750,115 -81%
BGIM
33
Brandywine Global Investment Management
Pennsylvania
$1.3M +$8.82K +2,150 +0.6%
WANY
34
Wealthspire Advisors (New York)
New York
$1.3M +$1.39M +337,770 New
PP
35
PDT Partners
New York
$1.26M -$282K -68,782 -17%
CCM
36
Cadence Capital Management
Massachusetts
$1.24M -$68.1K -16,593 -5%
Russell Investments Group
37
Russell Investments Group
United Kingdom
$1.23M +$330K +80,329 +34%
CS
38
Credit Suisse
Switzerland
$1.23M -$994K -242,113 -43%
Los Angeles Capital Management
39
Los Angeles Capital Management
California
$1.21M +$856K +208,445 +196%
TCM
40
Tanaka Capital Management
New York
$1.07M -$19.1K -4,650 -2%
Federated Hermes
41
Federated Hermes
Pennsylvania
$1M +$1.03M +251,854 +2,696%
Barclays
42
Barclays
United Kingdom
$981K +$581K +141,623 +125%
Jacobs Levy Equity Management
43
Jacobs Levy Equity Management
New Jersey
$956K +$97.5K +23,751 +11%
Squarepoint
44
Squarepoint
New York
$952K -$3.11M -756,848 -75%
RJFSA
45
Raymond James Financial Services Advisors
Florida
$912K – – –
WVP
46
Worth Venture Partners
New Jersey
$903K +$963K +234,625 New
Wells Fargo
47
Wells Fargo
California
$869K -$1.12M -273,078 -55%
California Public Employees Retirement System
48
California Public Employees Retirement System
California
$867K +$86.6K +21,100 +10%
CIA
49
Capital Impact Advisors
Massachusetts
$782K +$95.5K +23,265 +13%
Group One Trading
50
Group One Trading
Illinois
$777K +$155K +37,795 +23%
1
2
3 4 5

CPRX Hedge Fund Activity: Q1 2020 in Review

131 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Catalyst Pharmaceutical (CPRX) for Q1 2020, worth a combined $254M — up 7.8% from $236M a quarter earlier.

Buyers outnumbered sellers: 21 funds opened new CPRX positions and 19 closed out — a net gain of 2 holders — while 44 added to existing stakes and 49 trimmed.

The largest buyer was Mangrove Partners, adding an estimated $11.5M. The largest seller was Nuveen, cutting an estimated $7.18M.

  • 131 institutional investors held Catalyst Pharmaceutical (CPRX) as of Q1 2020, up from 130 in Q4 2019.
  • Funds reported $254M of Catalyst Pharmaceutical stock for Q1 2020, up 7.8% quarter-over-quarter.
  • 21 funds opened new Catalyst Pharmaceutical positions in Q1 2020 and 19 closed out, a net change of +2 holders.
  • The largest Catalyst Pharmaceutical buyer in Q1 2020 was Mangrove Partners, an estimated $11.5M added.
  • The largest Catalyst Pharmaceutical seller in Q1 2020 was Nuveen, an estimated $7.18M sold.

Based on aggregated 13F filings for Q1 2020.